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ABSTRACT
Fluoroquinolone resistance and type III secretion system (TTSS) virulence are independently
associated in Pseudomonas aeruginosa infections with poor patient outcomes. In the present study,
the virulence of ﬂuoroquinolone-susceptible and -resistant isolates of P. aeruginosa was compared,
focusing on TTSS virulence. Clinical isolates (n = 45) exhibiting a broad range of susceptibilities to
ﬂuoroquinolones, with differing mechanisms of resistance and associated with varying disease sites,
were selected for the study. PCR, Southern blot and western immunoblot analyses were performed to
determine the presence of TTSS-encoding genes and secretion of gene products. The cytotoxicity of the
clinical isolates towards human lung epithelial cells was also determined. Clinical isolates encoding
only the exoS cytotoxin gene occurred more frequently than those encoding only exoU (62% vs. 27%;
p 0.0007). Compared with exoS+ isolates, exoU+ isolates were more likely to be ﬂuoroquinolone-
resistant (92% vs. 61%, p 0.05) and to exhibit both a gyrA mutation and the efﬂux pump
over-expressed (EPO) phenotype (91% vs. 59%; p 0.06). Almost all exoU+ strains secreted ExoU and
exhibited increased cytotoxicity compared with ExoS-secreting strains (7% vs. 92.5%, relative to a
PA103 reference strain control). These data suggest that exoU+ and ﬂuoroquinolone resistance may be
co-selected traits that result in highly virulent and resistant strains. Adverse outcomes associated
with infections caused by ﬂuoroquinolone-resistant strains may, in part, be attributable to this
co-association, which warrants further clinical investigation.
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INTRODUCTION
Pseudomonas aeruginosa is an opportunistic patho-
gen that is capable of causing a wide spectrum
of acute infections in hospitalised and immuno-
compromised patients, as well as chronic lung
infections in patients with cystic ﬁbrosis. Among
the multitude of virulence determinants pos-
sessed by P. aeruginosa, the type III secretion
system (TTSS) has been implicated in the patho-
genesis of acute infections. The TTSS allows the
bacterium to inject cytotoxins (ExoS, ExoU, ExoY
and ExoT) into mammalian cells, to evade the
host immune response by preventing phagocy-
tosis through modulation of actin cytoskeleton
dynamics within host cells, and to inhibit mam-
malian DNA synthesis, leading to host cell death
[1–5].
Genes encoding the cytotoxins ExoS and ExoU
are present as variable traits in P. aeruginosa,
depending on the disease site or background
[6,7]. In a mouse model of acute pneumonia,
secretion of ExoU had the greatest impact on
mortality, bacterial persistence and dissemination
in the lung, followed by ExoS and ExoT [4].
Consistent with this ﬁnding, two clinical studies
have demonstrated that pneumonia caused by
P. aeruginosa strains secreting ExoU and PcrV
(part of the injection apparatus of the TTSS) was
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characterised by severe disease and excess mor-
tality [8,9].
In addition, P. aeruginosa has a remarkable
ability to develop resistance to antimicrobial
agents. With ﬂuoroquinolones becoming the
class of antibiotics most commonly prescribed
to adults in the USA [10], the rate of ﬂuoroqu-
inolone resistance has tripled in the last decade,
according to a large survey of Gram-negative
bacterial isolates from intensive care units
throughout the USA [11]. More recent data
indicate that the prevalence of ﬂuoroquinolone-
resistant P. aeruginosa now exceeds 50% in some
US hospitals [12]. Many of these strains are also
multidrug-resistant [11,13], which severely limits
the treatment options available. Over-expression
of broad-substrate efﬂux pumps (EPs) [14–18]
and ⁄ or target site (e.g., gyrA) mutations [19] are
responsible for resistance to the ﬂuoroquinolones
in P. aeruginosa. Kriengkauykiat et al. [20] found
that the efﬂux pump over-expressed (EPO) phe-
notype was present in 61% of ﬂuoroquinolone-
resistant P. aeruginosa clinical isolates, and
preliminary experiments have suggested that
most (72%) ﬂuoroquinolone-resistant strains
also carry gyrA mutation(s) (J. Kriengkauykiat,
M. Kadano, N. Gotoh, E. Porter, T. Synold and
A. Wong-Beringer, unpublished results).
More importantly, a case-control study
revealed that patients infected with ﬂuoroquino-
lone-resistant P. aeruginosa had more prolonged
illness and three-fold higher mortality rates com-
pared with patients infected with susceptible
strains, even after controlling for the underlying
severity of illness [13]. It is possible that ﬂuoro-
quinolone resistance is associated with increased
virulence, thereby providing a biological expla-
nation for the adverse outcomes observed. Other
studies have provided evidence to link the mul-
tidrug resistance phenotype with the presence of
exoU in ocular isolates of P. aeruginosa associated
with keratitis [21] and in isolates shown to be
highly disruptive to the intestinal epithelial bar-
rier [22]. However, the possibility of a speciﬁc
relationship between ﬂuoroquinolone resistance
and P. aeruginosa virulence has not been explored
previously. Accordingly, the present study aimed
to determine whether a correlation exists between
the presence of type III cytotoxin-encoding viru-
lence genes, secretion phenotypes and corre-
sponding in-vitro cytotoxicity, and the degree
and mechanisms of ﬂuoroquinolone resistance.
MATERIALS AND METHODS
Bacteria
Forty-ﬁve isolates were selected from among a collection of
143 clinical isolates that had been characterised previously
for: (i) ﬂuoroquinolone susceptibility, based on levoﬂoxacin
MICs determined by broth microdilution and interpreted
according to CLSI criteria [23]; (ii) gyrA mutations, detected
by PCR [24] and sequencing of ampliﬁed products; (iii) the
EPO phenotype, based on a comparison of levoﬂoxacin
MICs in the presence and absence of the EP inhibitor MC-04,
124 (Mpex Pharmaceuticals, San Diego, CA, USA), which is
a dipeptide amide compound that has been shown to
broadly inhibit several known multidrug (MexAB-
OprM, MexCD-OprJ and MexEF-OprN) and possibly other
EPs in P. aeruginosa [25]; and (iv) clonal relationships,
determined according to pulsed-ﬁeld gel electrophoresis
using standard procedures and chromosomal DNA digested
with SpeI (New England Biolabs, Beverly, MA, USA).
Isolates were considered to represent unique clones if they
exhibited more than three band fragment differences from
all other isolates.
Isolates selected for the present study exhibited a range of
susceptibilities to ﬂuoroquinolones (levoﬂoxacin MICs 0.25–
128 mg ⁄L), showed various degrees of EP involvement (0–64-
fold decrease in the levoﬂoxacin MIC in the presence of an EP
inhibitor), were with and without gyrA mutations, were
considered to represent unique clones (according to the results
of pulsed-ﬁeld gel electrophoresis), and were recovered from
various body sites. None of the patients had cystic ﬁbrosis
or neutropenia. Control P. aeruginosa strains included
PAO1 (exoS+ ⁄ exoT+ ⁄ exoY+) and PA103 (exoU+ ⁄ exoT+ ⁄ exoY+)
[2,3,26,27].
Analysis of TTSS genotype by multiplex PCR and Southern
blot hybridisations
P. aeruginosa isolates were cultured overnight in 200 lL of
Luria broth in 96-well plates at 37C without shaking, and this
was followed by dilution to either 1:10 or 1:100 in H2O.
Multiplex PCRs were performed as described previously,
using primers for exoU, exoS, exoT and exoY [28]. Products were
visualised following electrophoresis on agarose 3% w ⁄v gels
stained with ethidium bromide and viewed under UV light. To
test for the presence of pcrV, an additional PCR was performed
under the same conditions using primers PcrV forward (5¢-AT
GGAAGTCAGAAACCTTAA) and PcrV reverse (5¢-CTA
GATCGCGCTGAGAATGT). The resulting PCR products were
visualised on agarose 1% w ⁄v gels.
Southern hybridisation analyses were performed using
PCR amplicons generated from pcrV, exoY, exoS, exoT and
exoU (primer sequences available from the corresponding
author upon request). PCR products were labelled using the
DIG system (Roche, Indianapolis, IN, USA) according to the
manufacturer’s protocol. Chromosomal DNA was isolated
from all strains using a Genelute kit (Sigma Aldrich,
St Louis, MO, USA) according to the manufacturer’s instruc-
tions. DNA was quantiﬁed by spectrophotometric measure-
ments, after which 10 lg were digested with BamHI before
separation on agarose 0.9% w ⁄v gels. DNA was blotted on
positively charged nylon membranes (Bio-Rad, Hercules,
CA, USA) and probed using DIG-labelled fragments of each
gene.
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Western blot analysis of TTSS protein secretion
To synchronise cultures, all P. aeruginosa isolates were grown
overnight in 5 mL of Luria broth at 37C with shaking.
Cultures were harvested and the pellets were washed twice
with MINS (type III secretion-inducing medium [29]) before
resuspension in 500 lL of MINS. This inoculum was added
to 5 mL of MINS and incubated with shaking (350 rpm) for
24 h. All clinical isolates grew equally well in this medium.
Cultures were harvested and the cell pellets (cellular
fraction) were lysed with SDS buffer (SDS 1% w ⁄v,
250 mM Tris-HCl, pH 7.0). Supernatant (secreted fraction)
was carefully removed and concentrated at 4C using
Centricon tubes (10 000 MWCO; Millipore, Billercia, MA,
USA). All cellular and secreted fractions were boiled and
protein contents were quantiﬁed using the Bio-Rad Dc
protein assay (Bio-Rad). Standardised total protein (20 lg)
of each fraction from each isolate was separated on poly-
acrylamide 12% w ⁄v criterion gels (Bio-Rad), and this was
followed by immunoblot analysis using monoclonal anti-
bodies against ExoS, ExoU and PcrV as described previously
[30].
Cytotoxicity assay
BEAS-2B human lung epithelial cells (200 lL) were seeded
at a density of 2.5 · 105 ⁄mL into 96-well plates (Becton
Dickinson, Franklin Lakes, NJ, USA) in Dulbecco’s Modiﬁed
Eagle’s Medium supplemented with bovine calf serum
10% v ⁄v, and were then incubated in a CO2 5% v ⁄v
environment at 37C for 24 h. Overnight bacterial cultures
(1 mL) were washed twice in Lactated Ringer’s solution and
resuspended in 100 lL of Lactated Ringer’s ⁄phosphate-buf-
fered saline buffer (2:1). Bacteria (5 · 106 CFU) were added
to each well in triplicate and incubated at 37C for 3 h.
The supernatant (100 lL) was removed from triplicate wells
for each bacterial isolate and centrifuged at 4C for 3 min.
Cell-free supernatant (50 lL) was assayed using the Cyto-
tox96 Non-radioactive Cytotoxicity Assay (Promega, Madi-
son, WI, USA). Cytotoxicity was expressed as percentage
activity at 3 h post-infection relative to that of the P. aeru-
ginosa PAO1 (ExoS-secreting) and PA103 (ExoU-secreting)
control strains. The clinical isolates were considered to be
non-cytotoxic if their cytotoxicity was less than that of
PAO1.
Statistical analysis
The clinical isolates were grouped according to the presence of
TTSS-encoding genes and then compared for their distribution
according to disease site, ﬂuoroquinolone susceptibility and
putative resistance mechanisms. In addition, the presence of
TTSS-encoding genes was correlated with the secretion of
encoded proteins and in-vitro cytotoxicity. Chi-square or
Fisher’s exact tests were used as appropriate, with p £0.05
considered to be statistically signiﬁcant.
RESULTS
Clinical isolates
Among the 45 clinical isolates of P. aeruginosa
obtained from adults and children, the site of
isolation was known for 40 isolates, with most
being obtained from sputum, followed by wound,
urine and blood (Table 1). Of these, 29 isolates
caused infections, i.e., in the lungs (n = 15), in a
wound (n = 6), in blood (n = 4) and in urine
(n = 4).
Distribution of genes encoding type III
secretion proteins
TTSS genotyping, according to PCR for the pcrV,
exoU, exoS, exoT and exoY genes, revealed that all
45 clinical isolates carried exoT, 91% carried pcrV,
and 84% carried exoY. Most (89%) carried either
exoS or exoU, while 9% carried both, and 2%
carried neither. Southern hybridisation analyses
corroborated these ﬁndings (data not shown).
Clinical isolates carried exoSmore frequently than
exoU alone (62% vs. 27%, p 0.0007) (Table 1).
In agreement with data published previously
[6,7], the distribution of exoU and exoS varied
according to disease site and was, in general,
Table 1. Distribution of type III
secretion system genes among clin-
ical isolates of Pseudomonas aerugin-
osa according to disease site,
ﬂuoroquinolone resistance and cyto-
toxic phenotype
Characteristics exoU+ exoS+ exoU+ ⁄ exoS+ exoU) ⁄ exoS)
Overall n = 45a 12 (27%) 28 (62%) 4 (9%) 1 (2%)
Sourceb
Sputum 5 (23%) 14 (64%), p 0.04 3 (14%) 0
Wound 5 (63%) 2 (25%), p 0.04 0 1 (13%)
Urine 0 6 (100%) 0 0
Blood 2 (50%) 2 (50%) 0 0
Unknown 0 4 0 0
LVX-resistant (MIC ‡4 mg ⁄L) 11 (92%), p 0.05 17 (61%), p 0.05 1 (25%) 0
Resistance mechanism
EPO + gyrA 10 (91%), p 0.06 10 (59%), p 0.06 1 (100%) –
EPO alone 0 4 (24%) – –
gyrA alone 1 (8%) 3 (18%) – –
EPO) ⁄ gyrA) 0 0 – –
Cytotoxic phenotype 12 (100%) 11 (61%) 3 (75%) 1 (100%)
LVX, levoﬂoxacin; EPO, efﬂux pump over-expressed phenotype; gyrA, mutation in DNA gyrase subunit A.
aAll isolates contained exoT.
bSource site known for 40 isolates.
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mutually exclusive. Compared to wound isolates,
those from sputum samples were 2.5-fold more
likely to carry exoS (64% vs. 25%, p 0.04). Nota-
bly, exoU+ isolates were associated signiﬁcantly
with ﬂuoroquinolone resistance when compared
with exoS+ isolates (92% vs. 61%, p 0.05). Based
on previously characterised ﬂuoroquinolone
MICs and putative resistance mechanisms, the
proportion of clinical isolates containing exoU
increased as the level of ﬂuoroquinolone resis-
tance (levoﬂoxacin MIC) increased (Fig. 1). All
but one exoU+ isolate (91%, 10 ⁄ 11) exhibited both
an EPO phenotype and a gyrA mutation, com-
pared with only 59% (10 ⁄ 17) of exoS+ isolates
(p 0.06; Table 1). Interestingly, three of the four
isolates harbouring both exoU and exoS, as well as
the single exoU) ⁄ exoS) isolates, were susceptible
to levoﬂoxacin. Only slight differences in the
proportion of isolates that carried pcrV (86–100%)
and exoY (75–100%) were observed among iso-
lates when grouped according to source and
resistance.
TTSS cytotoxin secretion phenotype
Intracellular production and secretion of ExoU,
ExoS and PcrV (crucial for efﬁcient TTSS intoxi-
cation) was determined under in-vitro inducing
conditions by immunoblot analyses of cell lysates
and cell-free supernatant fractions. All isolates
that carried exoU also produced the correspond-
ing protein, but only 75% actively secreted this
cytotoxin under inducing conditions. It is of note
that all isolates that carried exoU and displayed
the EPO phenotype also secreted ExoU, while two
of three exoU-carrying isolates that did not have
the EPO phenotype did not secrete the cytotoxin
(Fig. 2). Those isolates that secreted ExoU in high
concentrations also exhibited concomitantly high
levels of secreted PcrV (data not shown). Inter-
estingly, almost all of the isolates that failed to
secrete detectable levels of PcrV into the medium
under inducing conditions were found to encode
ExoS as their primary cytotoxin.
In-vitro cytotoxicity using the BEAS-2B
epithelial cell line
The in-vitro cytotoxicity of all isolates was deter-
mined using the BEAS-2B lung epithelial cell line
(Fig. 3). To establish a reference level for relative
cytotoxicity, PA103 (carrying exoU) was set
at 100%. PAO1 (carrying exoS) exhibited 11%
Fig. 1. Distribution of exoU and exoS genes according to
levoﬂoxacin MIC. The proportion of isolates carrying exoU
increases as the levoﬂoxacin MIC increases, with a con-
comitant decrease in the proportion of isolates carrying
exoS.
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Fig. 2. Immunoblot analysis to determine ExoU secretion
among 45 clinical isolates and control strains. O indicates
the efﬂux pump over-expressed (EPO) phenotype, and N
indicates no EPO phenotype. All isolates with the EPO
phenotype also secreted ExoU, while two of three isolates
without the EPO phenotype did not secrete the cytotoxin.
Sample 17 was re-analysed with an increased amount of
total protein.
Fig. 3. Cytotoxicity of clinical isolates according to type III
secretion system, genotype and ﬂuoroquinolone resistance.
Isolates carrying exoU were more cytotoxic and more
resistant than isolates carrying exoS.
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cytotoxicity relative to PA103. Isolates showing
<11% relative toxicity were considered to be very
poorly cytotoxic or non-cytotoxic. More than half
of the clinical isolates tested had cytotoxicity that
was greater than or equal to that of PAO1. All 12
ExoU-producing isolates were cytotoxic, with ﬁve
isolates exhibiting cytotoxicity greater than
PA103. Levoﬂoxacin MICs for the latter isolates
were 8, 16 and 64 mg ⁄L. In contrast, <40% (11 ⁄ 28)
of ExoS-producing isolates were cytotoxic when
compared with PAO1. Given that many of the
exoS-carrying isolates did not secrete appreciable
amounts of PcrV (crucial to effective TTSS intox-
ication) under in-vitro inducing conditions, it is
likely that they are also poor secretors in vivo, and
this may explain the absence of cytotoxicity
exhibited by these isolates. Relative to PA103,
the average cytotoxicity of exoS+ isolates was 7%
(range 3–52%), compared with 92% (range 13–
140%) for isolates carrying exoU. Fig. 4 illustrates
that there was a direct correlation between exoU
expression, cytotoxicity and the EPO phenotype
(Fig. 4).
DISCUSSION
Indirect evidence from epidemiological and out-
come studies suggests that antibiotic-resistant
P. aeruginosa clinical isolates may be associated
with increased virulence [13,31,32]. Fluoroquino-
lone resistance and expression of TTSS virulence
(speciﬁcally exoU) were associated independently
with poor outcomes in P. aeruginosa infections
[8,9,13]. Previous studies have linked multidrug
resistance in P. aeruginosa to exoU expression in
ocular isolates and in clinical isolates that highly
disrupt the intestinal epithelial barrier [21,22]. The
present study revealed that the overall distribu-
tion of TTSS genes, and the distribution according
to disease site, were consistent with the results of
previous investigations that examined both clin-
ical and environmental isolates [6,7]. The exoT
gene was found in all clinical isolates, while the
presence of exoU and exoS varied. The prevalence
of exoU+ isolates varied according to source, with
30% of sputum isolates, compared with 60% of
wound isolates, being positive for exoU. These
observations concur with previous studies,
in which 25–30% of respiratory isolates were
reported to carry exoU [6,9]. While more clinical
isolates carried exoS than exoU, the exoU+ sub-
population appeared to contain more ﬂuoroqui-
nolone-resistant isolates. Nevertheless, it is
possible that more virulent exoU-containing iso-
lates caused more disease symptoms, and were
thus exposed to more antimicrobial agents (i.e.,
levoﬂoxacin), thereby giving rise to the emer-
gence of resistance. In the present ﬂuoroquino-
lone-resistant cohort, possession of both a gyrA
mutation and the EPO phenotype was found
in 91% of exoU+ isolates, compared with only
59% of the exoS+ isolates, with the result that
exoU+ isolates were more resistant than exoS+
isolates. Thus, it appears that exoU and increased
resistance to levoﬂoxacin may be co-selected
traits.
In addition, all isolates harbouring exoU also
produced the corresponding cytotoxin, and most
secreted it. Notably, all exoU+ isolates with
the EPO phenotype secreted the cytotoxin. As
expected, ExoU-secreting isolates were cytotoxic
to human lung epithelial cells in vitro. High-level
ﬂuoroquinolone-resistant isolates that secreted
ExoU were more cytotoxic than the control strain
PA103, which has been shown previously to cause
signiﬁcant mortality in animal models of acute
pneumonia [3,4]. Only about one-third of exoS+
isolates demonstrated a level of cytotoxicity
in vitro that exceeded that of PAO1, with another
third exhibiting poor or undetectable cytotoxicity
at 3 h post-infection. Collectively, these data
suggest that the co-selection of exoU+ and ﬂuoro-
quinolone resistance is more than simply chance.
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R2 = 0.1703
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Fig. 4. Correlation of ExoU secretion with cytotoxicity,
ﬂuoroquinolone resistance and the efﬂux pump over-
expressed (EPO) phenotype (all shown on a logarithmic
scale). The relative frequency of cytotoxicity (cyto), the
EPO phenotype (as measured by at least a three-fold
decrease in the levoﬂoxacin MIC (L-Dec) in the presence of
an efﬂux pump inhibitor) and ﬂuoroquinolone resistance
(levoﬂoxacin MIC, LVX MIC) increase as ExoU secretion
increases.
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Although the idea is speculative, highly viru-
lent and resistant strains of P. aeruginosa may
have evolved from acquisition of the exoU geno-
mic island through horizontal gene transfer,
thereby enhancing colonisation and survival in
various host environments [33]. Concomitantly,
development of mutations conferring resistance
to ﬂuoroquinolones as a result of heavy exposure
may have occurred, either in parallel or following
an assortive recombination of chromosomal re-
gions encoding resistance and virulence genes
[34]. Alternatively, Preisler et al. [35] have re-
ported that the gyrA mutations that confer ﬂuoro-
quinolone resistance also affect supercoiling of
DNA, which has been shown to affect virulence
gene expression [36–38]. Other studies have
revealed that inhibition of DNA gyrase with
antibiotics (i.e., novobiocin) speciﬁcally affects
transcription of type III virulence genes [36–39].
Thus, the potential for ﬂuoroquinolone resistance
to affect TTSS gene expression as a result of
changes in DNA supercoiling has already been
demonstrated in other bacterial species [36,37].
All of the exoU+ ﬂuoroquinolone-resistant
(MIC >2 mg ⁄L) isolates contained gyrA muta-
tions, suggesting that this mutation may affect
the virulence of isolates carrying exoU. More
detailed investigation is merited to elucidate the
exact nature of the mechanism by which changes
in DNA supercoiling, as a result of ﬂuoroquino-
lone-induced gyrA mutations, affect type III viru-
lence gene expression in clinical isolates of
P. aeruginosa. Similarly, the question of whether
over-expression of efﬂux pumps up-regulates
TTSS virulence expression deserves further study.
The present study revealed that exoU-contain-
ing isolates appeared to have a competitive
advantage by having the potential to be both
highly antibiotic-resistant and cytotoxic. A win-
dow of regulatory control may exist whereby
ﬂuoroquinolone resistance mechanisms and TTSS
virulence determinants are maximised to enhance
cytotoxicity in these isolates. This may explain the
over-representation of exoU among the ﬂuoroqu-
inolone-resistant isolates in the present cohort,
supporting the notion that isolates belonging to
different genotypes can vary in their adaptive
responses to environmental stimuli, e.g., exposure
to ﬂuoroquinolones. Further study is required to
conﬁrm whether clinical isolates harbouring exoU
are selected preferentially in the presence of
ﬂuoroquinolones to develop high-level resistance
and enhanced cytotoxicity. The positive relation-
ship between ﬂuoroquinolone resistance, carriage
of exoU and enhanced cytotoxicity observed in the
present study suggests that adverse outcomes
connected with ﬂuoroquinolone-resistant P. aeru-
ginosa infections may be attributable to associated
enhanced TTSS virulence.
In summary, the present study provided evi-
dence suggestive of co-selection of ﬂuoroquino-
lone resistance and enhanced TTSS virulence in
P. aeruginosa clinical isolates harbouring exoU.
These observations require conﬁrmation with a
larger sample size and a study of associated
clinical outcomes, as well as a thorough investi-
gation of the molecular basis by which ExoU-
secreting ﬂuoroquinolone-resistant isolates
develop an evolutionary advantage in the clinical
setting. If future studies reveal that overuse of
ﬂuoroquinolones leads to both resistance and
enhanced virulence in P. aeruginosa, the practice
of widespread ﬂuoroquinolone prescribing will
need to be curtailed, and novel anti-virulence
therapeutic strategies will need to be developed
with the utmost urgency.
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